Ipsilateral major or disabling stroke · asymptomatic carotid stenosis
Lipid‐lowering agent showed no clear difference in ipsilateral major or disabling stroke (only reported for two… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events (hospital records/every 6 weeks) · asymptomatic carotid stenosis
Lipid‐lowering agent showed no clear difference in adverse events (only reported for two studies: one study used CT… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Hospital or 30‐day mortality
It is very uncertain whether the intervention changes hospital or 30‐day mortality (very low certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 ‐ total compared with placebo or standard care alone (high certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 compared with human immunoglobulin (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at up to day 28 · outpatients withmild disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical worsening: need for invasive mechanical ventilation, or… compared with placebo or standard care alone (high certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Time to symptom resolution · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in time to symptom resolution (absolute effect calculated for day 12) compared with placebo or standard care alone (low certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · outpatients withmild disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma probably leads to lower admission to hospital or death within 28 days compared with standard plasma (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · individuals with moderate to severe disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes clinical worsening: need for invasive mechanical ventilation, or… compared with standard plasma (very low certainty).
1 finding from 1 review
Time in hospital(days) · children with severe dehydration due to diarrhoea
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Tranexamic acid changes risk of reoperation or repeat procedure for bleeding within 7 days compared with placebo (very low certainty).
1 finding from 1 review
Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).
1 finding from 1 review